Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study

Journal of Human Hypertension

Volumn 24, Issue 2, 2010, Pages 93-103

  Palatini, P ^a   Jung, W ^b   Shlyakhto, E ^c   Botha, J ^d   Bush, C ^e   Keefe, D L ^e  

^a UNIVERSITY OF PADOVA   (Italy)

^b Academic Hospital Villingen   (Germany)

^c ALMAZOV NATIONAL MEDICAL RESEARCH CENTRE   (Russian Federation)

^d Novartis Institutes of BioMedical Research   (Sweden)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Ambulatory blood pressure monitoring; Compliance; Direct renin inhibitor; Persistence

Indexed keywords

ALISKIREN; IRBESARTAN; RAMIPRIL;

ADULT; ARTICLE; ASTHENIA; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FLU LIKE SYNDROME; GASTROENTERITIS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS;

ADULT; AGED; AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BRAZIL; CANADA; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FUMARATES; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RAMIPRIL; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 75149195876     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2009.38     Document Type: Article

References (18)

1. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190-1196.
2. Egan BM, Lackland DT, Cutler NE. Awareness, knowledge, and attitudes of older Americans about high blood pressure: implications for health care policy, education, and research. Arch Intern Med 2003; 163: 681-687.
3. Clement DL, De Buyzere ML, De Bacquer DA, De Leeuw PW, Duprez DA, Fagard RH et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348: 2407-2415.
4. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ 2008; 336: 1114-1117.
5. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67: 1767-1792.
6. Limoges D, Dieterich H-A, Yeh C-M, Vaidyanathan S, Howard D, Dole WP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008; 46: 252-258. (Pubitemid 351663162)
7. Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos 2007; 35: 1418-1428.
8. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dosedependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
9. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-599.
10. Elliott HL, Elawad M, Wilkinson R, Singh SP. Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system. J Hypertens 2002; 20: 333-338.
11. Myers MG, Leenen FH. The impact of one or two missed doses on the duration of action of combined perindopril and indapamide. J Hum Hypertens 2007; 21: 86-93.
12. White WB, Lacourciere Y, Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17: 347-353.
13. Lacourciere Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients: a placebo-controlled, forced titration study. Candesartan/Losartan Study Investigators. Am J Hypertens 1999; 12: 1181-1187.
14. Goyal D, Chong AY, Watson RL, Prasad N, Watson RD. Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study. J Hum Hypertens 2007; 21: 525-530.
15. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 2004; 109: 2492-2499.
16. Uresin Y, Taylor AA, Kilo C, Tschope D, Santonastaso M, Ibram G et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-198.
17. Wood JM, Maibaum J, Rahuel J, Grutter MG, Cohen NC, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
18. Danser AH, Charney A, Feldman DL, Nussberger J, Fisher N, Hollenberg N. The renin rise with aliskiren: it's simply stoichiometry. Hypertension 2008; 51: e27-e28 (Letter)